Abstract

Oncolytic virotherapy behaves as a therapy with increased tumor selective targeting. Enormous amount of natural and genetically engineered anticancer viruses are currently being tested in clinical trials, with two viruses being clinically approved. H101 approved in 2005 showed increased tumor selectivity compared to the viruses studied previously to 2005. Whereas double mutated T-Vec, approved in 2015 showed further increase in tumor selectivity and tumor regression due to the insertion of GM-CSF. However, combinational therapy focusing the immunostimulatory properties of these viruses along with immune-checkpoint inhibitors has exhibited remarkable results over the monotherapy of oncolytic viruses, which shows the potential in becoming a standard treatment modality for cancer patients.

Keywords

virotherapy, oncology, T-Vec, H101, immunotherapy, monotherapy, combination therapy